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A B S T R A C T
Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease mainly caused by a
deﬁciency of arylsulfatase A activity. The typical clinical course of patients with the late infantile form includes a
regression in motor skills with progression to dysphagia, seizures, hypotonia and death. We present a case of a 4-
year-old female with rapidly progressive developmental regression with loss of motor milestones, spasticity and
dysphagia. MRI showed volume loss and markedly abnormal deep white matter. Enzymatic testing in one la-
boratory showed arylsulfatase A activity in their normal range. However, extraction of urine showed a large
increase in sulfatide excretion in a second laboratory. Measurement of arylsulfatase A in that laboratory showed
a partial decrease in arylsulfatase A activity measured under typical conditions (about 37% of the normal mean).
When the concentration of substrate in the assay was lowered to one quarter of that normally used, this in-
dividual had activity< 10% of controls. The patient was found to be homozygous for an unusual missense
mutation in the arylsulfatase A gene conﬁrming the diagnosis of MLD. This case illustrates the importance of
careful biochemical and molecular testing for MLD if there is suspicion of this diagnosis.
1. Introduction
Metachromatic leukodystrophy (MLD) (OMIM # 250100) is an au-
tosomal recessive lysosomal storage disease with a prevalence of ap-
proximately 0.6–1.9 per 100,000, which arises from deﬁcient activity of
the enzyme arylsulfatase A (ARSA) (EC 3.1.6.8) [5]. Less commonly, a
deﬁciency in sphingolipid activator protein, saposin B, is the cause.
ARSA is responsible for the degradation of sulfatides, a major compo-
nent of myelin in the nervous system. In MLD, excess sulfatides accu-
mulate in the central and peripheral nervous systems as well as other
visceral organs resulting in a spectrum of clinical disease.
Clinical manifestations of MLD vary based on functionality of the
ARSA enzyme. Late Infantile onset is generally associated with homo-
zygous or compound heterozygous null alleles of the ARSA gene re-
sulting in a rapid accumulation of sulfatides and earlier onset of disease
with rapid progression [3]. Patients typically present with regression of
motor skills, gait diﬃculties, ataxia and weakness within the ﬁrst
3 years of life [5]. The disease is progressive and patients develop
dysphagia and feeding intolerance, seizures, hypotonia, and peripheral
neuropathy. Patients with late infantile MLD die at a mean age of about
4 years. Individuals with juvenile and adult onset have a variety of
mutations in the ARSA gene (OMIM # 607574) that must result in some
residual ARSA activity explaining their later onset and the longer pro-
gression of disease. Juvenile patients typically present between 3 and
16 years of age with deterioration in intellectual performance along
with behavioral diﬃculties [5]. These individuals are usually com-
pound heterozygotes and have one null allele, resulting in no enzyme
activity, and one allele with a mutation that results in some residual
ARSA activity. Adult patients often present with a decrease in in-
tellectual capabilities, psychiatric issues and abnormal behavior. In-
dividuals with adult onset disease typically have two mutations that
result in some residual enzyme activity [1,3,4]. The clinical course is
slower than the late infantile and juvenile forms. Neurological symp-
toms can include gait disturbance, ataxia, seizures and peripheral
neuropathy.
The diagnosis of MLD has traditionally been made based on a
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combination of clinical suspicion, diagnostic imaging along with bio-
chemical and genetic testing. MRI ﬁndings include bilateral symmetric
abnormal T2 signal hyperintensities indicating white matter change.
The characteristic “leopard skin sign” or “tigroid pattern” results from
alternating stripes of bright demyelinated periventricular white matter
[8]. Measurement of low ARSA activity as part of a screen for lysosomal
storage disorders may result in a presumptive diagnosis. However,
ARSA activity will be normal if the patient has a deﬁciency of saposin B.
Also, ARSA activity can be low in individuals who do not have MLD if
they have two copies of the so-called pseudodeﬁciency (Pd) allele or
one copy of the Pd allele with an MLD-causing mutation on their other
allele. ARSA activity will be low in individuals with multiple sulfatase
deﬁciency (MSD). In patients with MSD the activities of other sulfatases
will also be low. The excretion of sulfatides in the urine is a deﬁnitive
test to conﬁrm the diagnosis of MLD, whether caused by defects in
ARSA or saposin B. Unaﬀected individuals do not excrete any detect-
able levels of lipid. However, it is also excreted in patients with MSD
along with glycosaminoglycans. Low ARSA activity and sulfatide ex-
cretion in the urine followed by the ﬁnding of disease-causing muta-
tions in the ARSA gene usually complete the diagnosis of MLD. How-
ever, often physicians send blood for an enzymatic testing panel to
screen for a storage disorder, including MLD, and normal results may
not prompt additional testing. We present a case of a patient with a
classic presentation of MLD, who had initial enzymatic testing in one
laboratory that reported ARSA activity in the normal range. Further
testing in another laboratory showed a large excretion of sulfatides in
the urine and lower than normal ARSA activity which lead to additional
enzymatic testing and molecular analysis that revealed a homozygous
variant of unknown signiﬁcance in the ARSA gene. While the diagnosis
of MLD is not diﬃcult in an experienced laboratory, there are caveats
that require careful consideration.
2. Clinical report
A 4-year-old female was evaluated in a primary care clinic to es-
tablish care and to discuss poor feeding. The patient and her family had
moved one month before from Kenya to the United States. The family
recalls that the patient was developing normally until the age of
30months. At that time, she developed a febrile illness for three days.
The mother took the patient to a health clinic during this time where
she was given an unknown medicine for a diagnosis of malaria. She
returned to her normal state of health, but within one to two weeks she
began to have diﬃculty walking. Four months later, the patient had lost
the ability to sit or walk independently or catch a ball. Due to her
limited function, she began to lose weight and developed contractures
in her extremities. One year after her initial illness, at approximately
three and a half years old, the patient no longer was able to commu-
nicate verbally, support her head independently, or tolerate solid food
in her diet. Her diet consisted solely of milk, which progressively be-
came harder to administer due to choking and gagging.
The patient was full-term at birth and had no previous medical
history, medications, or known allergies. She had received age-appro-
priate vaccinations in Kenya. A maternal aunt died at birth but the
etiology is unknown; otherwise, there was no family history of genetic
conditions, developmental regression, or autoimmune disease. There
were no similar episodes of symptoms in their Kenyan community. Her
older sibling who is six years old is healthy and developmentally ap-
propriate.
On physical examination, the patient was severely malnourished
(weight < 0.01 percentile) with diﬀuse truncal hypotonia and hy-
pertonicity in her extremities. She was able to orient towards stimuli
and had a social smile. Her musculoskeletal exam was pertinent for
contractures of her ankles with global muscle atrophy. She had sig-
niﬁcant head lag and was unable to support herself in the sitting po-
sition.
3. Methods and results
Due to her severe cachexia and failure to thrive, the patient was
admitted to the hospitalist service for further nutritional support and
further evaluation of her developmental regression. Neurology and
genetics were consulted on admission to assist with diagnostic man-
agement. Both services recommended a broad laboratory workup and
MRI to evaluate for a possible neurodegenerative condition.
MRI of the brain demonstrated markedly abnormal deep white
matter in a symmetric predominant conﬂuent periventricular distribu-
tion with involvement of the dentate nuclei, cerebellar white matter
and descending corticospinal tracts (Fig. 1). Given the clinical history,
the radiologists felt that the imaging was most consistent with MLD
versus Krabbe disease or a mitochondrial disorder. Shortly after ima-
ging was completed, blood was sent to one laboratory for testing, and
ARSA activity was reported as 82 nmol/h/mg protein with values>
62 nmol/h/mg protein being normal. The conclusion was that this in-
dividual did not have MLD or MSD. Urine and blood was then sent to
the laboratory of one of the authors (DAW) for testing. Initially a partial
deﬁciency of ARSA activity was measured (37% of the normal mean of
71 nmol/h/mg protein) using the typical assay conditions using ni-
trocatechol sulfate (10mM in the presence of 10% sodium chloride and
acetate buﬀer 0.5 M, pH 5.0 and 0.25mM sodium pyrophosphate) [9].
The activities of seven other lysosomal enzymes including galactocer-
ebrosidase to rule out Krabbe disease and arylsulfatase B to rule out
MSD were normal. A sample of urine was requested to see if sulfatides
were being excreted. As shown on Fig. 2, the patient was excreting large
amounts of sulfatides similar to other patients with MLD. It was possible
that this individual from Kenya could have unusual mutations that re-
sult in lowish ARSA activity under typical conditions but much lower
ARSA activity compared to “controls” if the substrate concentration was
lowered, a so-called Km mutation. When the nitrocatechol sulfate
concentration was lowered to one-quarter of that stated above
(2.5 mM), this individual had an ARSA value of 6.0 nmol/h/mg protein
compared to 58.6 nmol/h/mg protein for six controls. This value, about
10% of controls, is consistent with other patients conﬁrmed to have
MLD. Therefore, at the lower substrate concentration the deﬁciency of
ARSA activity is more obvious indicating that when higher substrate
concentrations are used the eﬀect of the missense mutation can be
partially overcome.
With the diagnosis of MLD conﬁrmed by sulfatide excretion and low
ARSA activity, mutation analysis on the ARSA gene was performed.
Analysis was done using next-generation sequencing (NGS) technology
Fig. 1. Metachromatic leukodystrophy. (a) T2-weighted MR image at the level
of central semiovale demonstrates bilateral conﬂuent areas of hyperintense
signal in the periventricular white matter with classic sparing of the subcortical
U ﬁbers. Also seen are linear and punctate hypointense foci, a ﬁnding that
suggests sparing of the white matter, also referred to as tigroid or leopard skin
appearance. (b) T2-weighted MR image at the level of posterior fossa demon-
strates abnormal hyperintense signal within cerebellar white matter as well.
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with a read depth of 1845×. Both full gene sequencing and deletion/
duplication analysis were performed for ARSA as well as 13 additional
genes related to similar phenotypes (including Neuronal Ceroid
Lipofuscinoses, Metachromatic Leukodystrophy, and Niemann-Pick
Disease Type C). Mutation analysis showed that this patient was
homozygous for a c.449C > G mutation resulting p.Pro150Arg.
Because this was considered to be a variant of unknown signiﬁcance,
additional technology was not used for conﬁrmatory analysis. Note:
there are two numbering systems for the ARSA cDNA and codons. The
one used here is six nucleotides longer than the original numbering
system resulting in the codons being two amino acids longer. It is
considered a variant of unknown signiﬁcance although it was pre-
viously found homozygous in a 1 year, 3-month-old Arabic female with
late infantile MLD [4]. However in that patient, the p.Pro150Arg mu-
tation was found in cis with the common Pd allele. The patient de-
scribed herein did not have the Pd allele. A diﬀerent mutation at the
same codon changing the Pro150 to Leu (formerly p.Pro148Leu) has
been reported in individuals with MLD [6], possibly pointing to the
importance of the proline at that position.
4. Discussion
Our case highlights the importance of index of suspicion, both with
respect to the clinician's evaluation of the patient and the laboratory
diagnostic work up. In this case, initial enzymatic testing was reported
as normal, but the clinical and neurodiagnostic evaluation indicated
more laboratory testing was indicated. When blood and urine were sent
to a diﬀerent laboratory, a partial deﬁciency of ARSA activity was
found pointing to the need for additional testing. The ﬁnding that the
patient excreted a large amount of sulfatide in urine indicted that a
diagnosis of MLD was a strong possibility. It is known that certain
missense mutations, changing an amino acid, may aﬀect the way the
enzyme handles the substrate. With some mutations, the activity is
completely knocked out, leaving little or no residual activity, but in
some cases the amino acid change may make the enzyme work less
eﬃciently. This may be partially overcome by raising the substrate
concentration. At lower concentrations of substrate, the eﬀect of the
mutation may be more obvious. This appears to be the situation in this
patient.
While biochemical studies including enzymatic testing and analyte
evaluation remain a valuable tool for accurate diagnosis of patients
with MLD and other genetic disorders we note that molecular studies
are becoming an additional component in the diagnosis. Nearly 300
mutations have been described in the ARSA gene. The ARSA gene is
located on chromosome 22q13.33 and is responsible for the coding of
ARSA. The alleles c.465+ 1G > A, c.1283C > T and c.542 T > G are
common disease variants, and are associated with a partial or total
disruption of ARSA activity [4]. In addition to disease-causing muta-
tions, there are additional mutations that do not result in disease when
inherited as homozygous mutations or as compound heterozygous with
disease-causing mutations. The common so-called Pd allele can result in
quite low ARSA activity in the laboratory and can result in an erroneous
diagnosis. However, individuals with one or two copies of the Pd allele
and no disease-causing mutations on at least one allele do not excrete
sulfatides. It appears that approximately 10–15% of normal ARSA en-
zymatic activity is suﬃcient to hydrolyze the turnover of sulfatides and
prevent clinical complications. It is not possible for measurement of
residual ARSA activity in the laboratory using synthetic substrate to
predict the disease phenotype. However, the identiﬁcation of certain
mutations in the ARSA gene can in some cases predict whether an in-
dividual will have a late infantile onset or a later onset. It should be
noted that this individual has a later onset of disease than the pre-
viously reported patient homozygous for this same mutation, however
the previously reported individual had the Pd allele in cis with the
p.Pro150Arg mutation [4]. The ﬁnding of the Pd allele in cis with an-
other mutation may lower the ARSA activity and therefore change the
phenotype. The onset and progression of the disease in juvenile and
adult patients is very diﬃcult to predict. In the case of newly described
mutations or when only found heterozygous in very few patients it may
be diﬃcult to determine if the mutation is “severe” or “mild.”
There are limited treatment options for individuals diagnosed with
MLD. Recent studies involving autologous hematopoietic stem cell
transplantation using virally transduced blood stem cells have been
reported [2]. Better outcomes are reported in patients treated before
neurologic symptoms are obvious but the long-term success of the ap-
proach is still to be determined. Any treatment option relies on rapid
and accurate diagnosis of the individual, thus indicating the potential
importance of including testing for MLD on the newborn screen. Our
case highlights the importance of the need for urine sulfatides and
molecular testing if a diagnosis of MLD is suspected.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgmr.2019.100460.
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